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 Case Presentation
A 43-year-old Hispanic male originally from Honduras pre-
sented to the emergency room with cough producing yellow 
sputum for 1 month, with recent change to blood tinged over 
the previous days. His past medical history was pertinent for 
hypertension and end stage renal disease requiring thrice 
weekly hemodialysis. He had missed dialysis for the previ-
ous week prior to presentation due to bad weather. He also 
reported fever, chills, and sore throat with the onset of 
hemoptysis. Of note, the patient had presented to another 
local hospital 2  months prior with similar symptoms of 
hemoptysis. He was evaluated by gastroenterology and oto-
laryngology and an endoscopy and laryngoscopy were per-
formed. There were no obvious signs of bleeding but 
endoscopy did note blood emanating from the larynx. At pre-
sentation, his physical exam was notable for bilateral inspira-
tory rales with normal vital signs including oxygen saturation 
of 98% on room air.
He was initially diagnosed with end-stage renal failure 
18  months prior following a motor vehicle accident. The 
patient was uninjured but was noted to have a serum creati-
nine of 21 mg/dL. A renal ultrasound showed renal paren-
chymal disease attributed to long-standing hypertension. He 
was started on hemodialysis. The patient had lived in the 
United States for the previous 10 years with no recent travel 
or sick contacts. He denied any use of tobacco, alcohol, or 
illicit drug use. He previously worked as a roofer, but was 
currently unemployed due to his dialysis dependence.
At the time of presentation, his laboratory data was nota-
ble for anemia with hemoglobin of 5.9  g/dL, Potassium 
6.6 mmol/L, BNP 2092 pg/mL and serum creatinine 23 mg/
dL. A chest X-ray showed multifocal bilateral alveolar opac-
ities (Figs. 33.1 and 33.2). The patient was initially treated 
with hemodialysis, broad spectrum antibiotics, and placed in 
respiratory isolation for evaluation of tuberculosis. The 
patient reported that his hemoptysis improved significantly 
following serial sessions of dialysis, yet chest imaging 
remained unchanged. Sputum culture, respiratory viral anti-
gen panel, and AFB smears were negative. A bronchoscopy 
was performed 4 days after admission and revealed a pro-
gressively bloody bronchoalveolar lavage (Fig. 33.3) consis-
tent with a diagnosis of diffuse alveolar hemorrhage. 
Serologic analysis confirmed the diagnosis.
Question
What is the diagnosis?
Answer Capillaritis with diffuse alveolar hemorrhage.
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Fig. 33.1 Chest X-ray at initial presentation showing multifocal bilat-
eral alveolar opacities
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This patient presented with hemoptysis confirmed to be 
diffuse alveolar hemorrhage and chronic renal failure. The 
initial suspected etiology was volume overload due to missed 
dialysis sessions due to the elevated BNP level. The patient 
was treated conservatively with dialysis and while his 
reported hemoptysis improved, his chest X-ray showed per-
sistent alveolar infiltrates. The serologic analysis that con-
firmed the diagnosis included Antinuclear Antibody of 
1:360, P-ANCA positivity, and antibody to Myeloperoxidase 
of greater than 8.0 units. The constellation of diffuse alveolar 
hemorrhage, renal involvement, and p-ANCA/MPO positiv-
ity confirmed a diagnosis of Microscopic Polyangiitis. 
Imaging of the sinuses showed no signs of inflammation of 
the upper respiratory tract. The patient was treated with pred-
nisone and cyclophosphamide pulse dosing for six doses. He 
had one subsequent episode of hemoptysis requiring hospi-
talization 1  month after initial presentation. In general, he 
responded well to treatment and was weaned from cortico-
steroids over the next 3 months after completion of cyclo-
phosphamide with improvement on chest imaging (Fig. 33.4).
 Principles of Management
 Differential Diagnosis
The differential diagnosis for diffuse alveolar hemorrhage 
can be quite extensive ranging from autoimmune to coagu-
lopathy to medications. Three characteristic patterns have 
been identified: Capillaritis, ‘Bland’ pulmonary hemorrhage, 
and alveolar bleeding due to another process [1, 2]. 
Capillaritis is the most common cause of DAH and is typi-
cally a result of antibody-mediated cell damage. Autoimmune 
conditions associated with DAH include antineutrophil cyto-
plasmic antibody (ANCA) associated vasculitides, 
Goodpasture Syndrome, Systemic Lupus Erythematosus 
(Table 33.1). Initial evaluation of a patient with hemoptysis 
and suspected diffuse alveolar hemorrhage typically includes 
fiberoptic bronchoscopy to identify a source of bleeding, 
identification of potential infectious etiologies, and serologic 
workup for autoimmune conditions. DAH should be distin-
guished from other causes of pulmonary hemorrhage caused 
by localized pulmonary abnormalities and the bronchial 
circulation.
a b
Fig. 33.2 (a, b) Chest CT images performed after hemodialysis showing diffuse bilateral alveolar opacities
Fig. 33.3 Sequential bronchoalveolar lavages starting left to right 
showing progressively bloody return
H. Desai et al.
255
a b
Fig. 33.4 (a, b) Chest CT images performed after 1 year of immunosuppressive treatment showing resolution of alveolar opacities
Table 33.1 Causes of diffuse alveolar hemorrhage
Capillaritis
Granulomatosis with polyangiitis (GPA)
Churg-Strauss syndrome
Microscopic polyangiitis (MPA)
Isolated pauci-immune pulmonary capillaritis
Idiopathic pauci-immune glomerulonephritis
Primary immune complex-mediated vasculitis
Goodpasture’s syndrome
Henoch-Schonlein purpura
Systemic lupus erythematosus
Rheumatoid arthritis
Antiphospholipid antibody syndrome
Mixed connective tissue disease
Polymyositis/dermatomyositis
Essential cryoglobulinemia
Behcet’s disease
Acute lung transplantation rejection
Bland pulmonary hemorrhage
Idiopathic pulmonary hemosiderosis
Coagulopathy: Anticoagulants, anti-platelet, thrombolytics, DIC
Mitral stenosis, pulmonary veno-occlusive disease
Infection: Human immunodeficiency virus infection, infective 
endocarditis
Toxin or inhalation injury: Isocyanates, crack cocaine, retinoic acid
Drug-associated disease: Propylthiouracil, diphenylhydantoin, 
amiodarone, mitomycin,
D-penicillamine, sirolimus, methotrexate, haloperidol, 
nitrofurantoin, gold,
All-trans-retinoic acid (ATRA), bleomycin, montelukast, zafirlukast, 
infliximab
Alveolar bleeding due to another condition
Diffuse alveolar damage
Pulmonary embolism
Sarcoidosis
High-altitude pulmonary edema, barotrauma
Infection: Invasive aspergillosis, cytomegalovirus infection, 
legionellosis, herpes simplex virus infection,
Mycoplasma, hantavirus infection, leptospirosis, other bacterial 
pneumoniae
Malignant conditions
Lymphangioleiomyomatosis
Tuberous sclerosis
Pulmonary capillary hemangiomatosis
Lymphangiography
 Classification
Microscopic Polyangiitis (MPA) is a member of the group of 
ANCA-associated vasculitides. This group also includes 
granulomatosis with polyangiitis (GPA) and eosinophilic 
granulomatosis with polyangiitis (EGPA or Churg-Strauss 
Syndrome). These diseases are characterized by pauci- 
immune necrotizing inflammation of small vessels [3]. MPA 
has previously been described as a subgroup of Polyarteritis 
Nodosa (small vessel form) and is distinguished from GPA 
by the absence of granuloma formation. MPA is most com-
monly associated with rapidly progressive glomerulonephri-
tis, although alveolar hemorrhage has been reported in up to 
12–29% of cases [4].
 Diagnosis
The diagnosis of ANCA-associated vasculitides is usually 
based upon findings of pulmonary and/or renal abnormalities 
with small-vessel necrotizing inflammation with the pres-
ence of auto-antibodies directed against neutrophilic anti-
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gens. Previously, ANCA directed antibodies were classified 
as cytoplasmic-pattern and perinuclear-patter, c-ANCA and 
p-ANCA, respectively. The two ANCA antigens commonly 
identified are proteinase 3 (PR3) and myeloperoxidase 
(MPO). MPO is more commonly associated with micro-
scopic polyangiitis with a sensitivity of 50–70%, although 
PR3 has been identified in cases of MPA with a sensitivity of 
26% [5–7]. Specificity of the combination of P-ANCA and 
MPO for ANCA-associated vasculitides is significantly 
greater at 99.8% [8]. In a review of patients with MPA and 
alveolar hemorrhage, 14 out of 27 patients revealed p-ANCA 
positivity while 11 out of 27 patients were c-ANCA positive 
[4]. Among those with p-ANCA antibodies, 12 out of 12 
patients were positive for MPO specific antibodies. The 
requirement of biopsy for the diagnosis of ANCA associated 
vasculitides remains controversial. In the correct clinical set-
ting with rapidly progressive glomerulonephritis, radio-
graphic abnormalities, and serologic confirmation of 
antibody, the diagnosis of ANCA-associated vasculitis can 
be determined. Given the relapsing nature of disease and 
requirements for prolonged immunosuppression, it is sug-
gested that confirmation of diagnosis by histopathology be 
determined whenever possible.
 Treatment
Treatment of diffuse alveolar hemorrhage can be categorized 
as follows—management of the underlying cause such as 
vasculitis, management of the pulmonary hemorrhage, and 
treatment of the hypoxia. Historically, initial management of 
ANCA-associated vasculitides has centered on immunosup-
pression with corticosteroids and cyclophosphamide. The 
goal of treatment is induction of remission and maintenance 
of disease suppression. Therapy is typically tailored to sever-
ity of disease, notably mild vs. moderate to severe. These 
determinations are based upon organ-threatening or life- 
threatening manifestations. Pulmonary involvement, and 
specifically alveolar hemorrhage, is considered moderate to 
severe disease. Plasmapheresis has been shown to be benefi-
cial in patients with diffuse alveolar hemorrhage and ANCA- 
associated vasculitis [9].
In many cases the pulmonary hemorrhage may be exacer-
bated by coagulopathy. Aggressive treatment with platelets 
for thrombocytopenia or fresh frozen plasma may be needed 
for control of the alveolar hemorrhage. There may be a com-
ponent of pulmonary congestion due to left heart pathology. 
Increasing positive end-expiratory pressure can improve pul-
monary congestion by decreasing afterload and preload thus 
helping with alveolar hemorrhage. Also, as a patient with 
DAH becomes hypoxemic, increasing peep may recruit more 
alveoli and improve oxygenation.
 Evidence Contour
 Supportive Care for Treatment of Hypoxia
Ventilation in the prone position has been mostly studied in 
patients with acute respiratory distress syndrome (ARDS), 
but may be useful to treat hypoxia due to pulmonary hemor-
rhage. In addition to facilitate recruitment and improved v/q 
mismatch prone position can improve drainage of the bloody 
secretions [10].
ECMO can also be used as a rescue therapy for DAH 
patients with severe hypoxemia and PaO2/FiO2 of 
<100 mmHg despite optimal ventilator settings [11]. There 
is concern that the ECMO circuit will need systemic antico-
agulation to prevent thrombus formation. There have been 
cases of performing ECMO without systemic anticoagula-
tion in patients with DAH without major complications. 
Another option is to use local citrate anticoagulation for the 
ECMO circuit. Reduced levels of anticoagulation represents 
another possibility although the optimal level of anticoagula-
tion is unknown [12, 13].
 Rituximab
Recently, there have been alternative treatment options identi-
fied in the treatment of ANCA-associated vasculitides. 
Cyclophosphamide carries several adverse reactions including 
cytopenias, infertility, bladder injury, and risk of malignancy. It 
has been identified that B lymphocytes play an integral in role 
in the pathogenicity of auto-immunity [14]. Rituximab, an anti-
CD20 monoclonal antibody, has been successfully used to 
reduce B-lymphocyte populations. Since 2010, there has been 
growing evidence that Rituximab can be used as an alternative 
to cyclophosphamide in the treatment of ANCA-associated 
vasculitides. When compared with cyclophosphamide, 
Rituximab was found to be non- inferior at induction of remis-
sion and maintenance of remission [15, 16]. In fact, Rituximab 
was found to be more effective for inducing remission of 
relapsing disease (67% vs. 42) [15]. Rituximab has been found 
to be superior to azathioprine in disease remission over 2 years 
[17]. Thus, rituximab has been shown to be a viable option for 
treatment of ANCA-associated vasculitides. While the patient 
in the case report was treated with cyclophosphamide, the use 
of rituximab could have been entertained.
 Recombinant Factor VII
Refractory diffuse alveolar hemorrhage can present a thera-
peutic dilemma. Systemic recombinant Factor VII has been 
successfully used in a case of massive hemoptysis due to 
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community acquired pneumonia [18]. Case reports and 
observational studies have shown a beneficial effect of intra-
pulmonary administration of activated recombinant factor 
VII in cases of refractory diffuse alveolar hemorrhage [19–
21]. Primarily, this practice has been shown to be beneficial 
in cases of DAH in allogeneic hematopoetic stem cell trans-
plant recipients. Limited case reports, however, have reported 
successful cessation of bleeding in cases of ANCA-associated 
vasculitis [19, 21]. At this time, use of recombinant Factor 
VII is considered “off-label” but further study is warranted 
for general use in cases of diffuse alveolar hemorrhage 
refractory to standard therapy.
 Tranexamic acid (TXA)
TXA has antifibrinolytic activity by binding to plasminogen 
which is the precursor to plasmin. The rationale for its use in 
DAH is that it can enhance the activity of depleted anti- 
fibrinolytic factors in ongoing bleeding sites along the bron-
chial tree [22]. Case series have reported that 500 mg/5 mL 
through a nebulizer may be an effective dose to halt pulmo-
nary hemorrhage. Although further research is needed, TXA 
can be a rescue therapy if a patient continues to bleed despite 
maximal therapy.
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